Custirsen
- Generic Name
- Custirsen
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 890056-27-6
- Unique Ingredient Identifier
- L26E95NLRK
- Background
Custirsen is a benzopyran with potential antineoplastic activity. Custirsen acts as a selective estrogen receptor modulator (SERM), inhibiting the proliferation of estrogen-sensitive breast cancer cells. This agent also inhibits growth and induces apoptosis of glioblastoma cells via a mechanism independent of estrogen receptor-related mechanisms. Custirsen is also being investigated in the treatment of primary brain tumors.
- Indication
Investigated for use/treatment in brain cancer and breast cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization
- Conditions
- Interventions
- First Posted Date
- 2013-06-11
- Last Posted Date
- 2016-10-10
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 155
- Registration Number
- NCT01874561
- Locations
- ๐บ๐ธ
Teva Investigational Site 10565, Lenexa, Kansas, United States
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
- First Posted Date
- 2012-06-28
- Last Posted Date
- 2016-07-01
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 700
- Registration Number
- NCT01630733
- Locations
- ๐ช๐ธ
Hospital Universitario La Paz, Madrid, Spain
๐บ๐ธUniversity Cancer Institute, Soynton Beach, Florida, United States
๐ช๐ธHospital Universitario Doctor Peset, Valencia, Spain
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2016-10-14
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 1022
- Registration Number
- NCT01188187
- Locations
- ๐ณ๐ฑ
Teva Investigational Site 852, Rotterdam, Netherlands
๐บ๐ธTeva Investigational Site 093, Marina del Rey, California, United States
๐บ๐ธTeva Investigational Site 100, Birmingham, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.